Array BioPharma Company Profile (NASDAQ:ARRY)

About Array BioPharma (NASDAQ:ARRY)

Array BioPharma logoArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ARRY
  • CUSIP: 04269X10
  • Web: www.arraybiopharma.com
Capitalization:
  • Market Cap: $2.16478 billion
  • Outstanding Shares: 171,442,000
Average Prices:
  • 50 Day Moving Avg: $11.49
  • 200 Day Moving Avg: $9.12
  • 52 Week Range: $5.36 - $13.40
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -19.18
  • P/E Growth: -1.15
Sales & Book Value:
  • Annual Revenue: $43.66 million
  • Price / Sales: 42.17
  • Book Value: $0.07 per share
  • Price / Book: 153.43
Profitability:
  • EBITDA: ($100,010,000.00)
  • Net Margins: -77.44%
  • Return on Equity: -1,187.18%
  • Return on Assets: -47.96%
Debt:
  • Debt-to-Equity Ratio: 11.42%
  • Current Ratio: 3.88%
  • Quick Ratio: 3.88%
Misc:
  • Average Volume: 4.12 million shs.
  • Beta: 2.16
  • Short Ratio: 8.62
 

Frequently Asked Questions for Array BioPharma (NASDAQ:ARRY)

What is Array BioPharma's stock symbol?

Array BioPharma trades on the NASDAQ under the ticker symbol "ARRY."

How were Array BioPharma's earnings last quarter?

Array BioPharma Inc. (NASDAQ:ARRY) released its earnings results on Wednesday, August, 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.04. The firm had revenue of $33.80 million for the quarter, compared to analyst estimates of $28.64 million. Array BioPharma had a negative return on equity of 1,187.18% and a negative net margin of 77.44%. Array BioPharma's revenue was down 21.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.17) earnings per share. View Array BioPharma's Earnings History.

When will Array BioPharma make its next earnings announcement?

Array BioPharma is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Array BioPharma.

Where is Array BioPharma's stock going? Where will Array BioPharma's stock price be in 2017?

7 analysts have issued 12 month target prices for Array BioPharma's stock. Their forecasts range from $9.00 to $18.00. On average, they anticipate Array BioPharma's stock price to reach $13.86 in the next year. View Analyst Ratings for Array BioPharma.

What are analysts saying about Array BioPharma stock?

Here are some recent quotes from research analysts about Array BioPharma stock:

  • 1. Cantor Fitzgerald analysts commented, "ARRY’s e-poster presentation of the safety lead in for the Phase III BEACON CRC study suggests that binimetinib/encorafenib could expand its market potential to colorectal cancer, which the shares do not currently reflect, in our view." (9/8/2017)
  • 2. According to Zacks Investment Research, "Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. " (8/11/2017)
  • 3. Cowen and Company analysts commented, "We see ARRY's decision to withdraw the NRAS NDA as prudent given the known modest efficacy benefit. The NRAS-mutant melanoma opportunity represented a modest 6% of our base model DCF, thus we lower our PT modestly from $15 to $14. We view recent share weakness and the passing of this 'risk' event as an especially attractive opportunity to firmly reiterate our Outperform rating on ARRY shares." (3/20/2017)

Are investors shorting Array BioPharma?

Array BioPharma saw a drop in short interest in the month of September. As of September 29th, there was short interest totalling 23,385,574 shares, a drop of 18.6% from the September 15th total of 28,717,062 shares. Based on an average trading volume of 4,448,232 shares, the short-interest ratio is currently 5.3 days. Currently, 12.0% of the company's stock are short sold.

Who are some of Array BioPharma's key competitors?

Who are Array BioPharma's key executives?

Array BioPharma's management team includes the folowing people:

  • Kyle A. Lefkoff, Independent Chairman of the Board
  • Ron R. Squarer, Chief Executive Officer, Director
  • Jason Haddock, Chief Financial Officer
  • Andrew R. Robbins, Chief Operating Officer
  • Nicholas A. Saccomano Ph.D., Chief Scientific Officer
  • Curtis Oltmans, General Counsel
  • Victor Sandor, Chief Medical Officer
  • Shalini Sharp, Director
  • Charles M. Baum M.D., Ph.D., Independent Director
  • Gwendolyn A. Fyfe M.D., Independent Director

Who owns Array BioPharma stock?

Array BioPharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include POINT72 ASSET MANAGEMENT, L.P. Total Shares: 9,194,118 (5.40%), Nationwide Fund Advisors (0.22%), Edge Wealth Management LLC (0.01%) and Fox Run Management L.L.C. (0.01%). Company insiders that own Array BioPharma stock include Charles M Baum, Kyle Lefkoff and Redmile Group, Llc. View Institutional Ownership Trends for Array BioPharma.

Who bought Array BioPharma stock? Who is buying Array BioPharma stock?

Array BioPharma's stock was purchased by a variety of institutional investors in the last quarter, including Nationwide Fund Advisors, Edge Wealth Management LLC and Fox Run Management L.L.C.. View Insider Buying and Selling for Array BioPharma.

How do I buy Array BioPharma stock?

Shares of Array BioPharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Array BioPharma's stock price today?

One share of Array BioPharma stock can currently be purchased for approximately $10.74.


MarketBeat Community Rating for Array BioPharma (NASDAQ ARRY)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  276 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  397
MarketBeat's community ratings are surveys of what our community members think about Array BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Array BioPharma (NASDAQ:ARRY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $13.86 (29.02% upside)
Consensus Price Target History for Array BioPharma (NASDAQ:ARRY)
Price Target History for Array BioPharma (NASDAQ:ARRY)
Analysts' Ratings History for Array BioPharma (NASDAQ:ARRY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/26/2017Cantor FitzgeraldReiterated RatingBuy$15.00HighView Rating Details
9/20/2017Piper Jaffray CompaniesReiterated RatingOverweight$14.00 -> $18.00LowView Rating Details
9/12/2017Jefferies Group LLCReiterated RatingBuy$9.00MediumView Rating Details
9/11/2017Cowen and CompanyReiterated RatingOutperform$14.00 -> $15.00HighView Rating Details
9/11/2017Stifel NicolausReiterated RatingBuy -> Buy$13.00 -> $15.00HighView Rating Details
9/11/2017J P Morgan Chase & CoReiterated RatingBuy$14.00HighView Rating Details
1/30/2017Leerink SwannDowngradeOutperform -> Market Perform$11.00N/AView Rating Details
6/2/2016SunTrust Banks, Inc.Initiated CoverageBuy$7.00N/AView Rating Details
(Data available from 10/24/2015 forward)

Earnings

Earnings History for Array BioPharma (NASDAQ:ARRY)
Earnings by Quarter for Array BioPharma (NASDAQ:ARRY)
Earnings History by Quarter for Array BioPharma (NASDAQ ARRY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2017($0.23)N/AView Earnings Details
8/9/2017Q4 2017($0.21)($0.17)$28.64 million$33.80 millionViewListenView Earnings Details
5/10/2017Q3 2017($0.16)($0.21)$38.28 million$33.28 millionViewN/AView Earnings Details
2/9/2017Q2 2017($0.18)($0.14)$31.90 million$44.50 millionViewListenView Earnings Details
11/1/2016Q117($0.16)($0.20)$32.47 million$39.30 millionViewListenView Earnings Details
8/4/2016Q416($0.14)($0.17)$41.51 million$43.20 millionViewListenView Earnings Details
5/3/2016Q316($0.12)($0.16)$30.35 million$43.00 millionViewListenView Earnings Details
2/2/2016Q216($0.06)($0.17)$32.70 million$35.40 millionViewListenView Earnings Details
11/4/2015Q116($0.18)($0.15)$14.02 million$16.20 millionViewListenView Earnings Details
8/3/2015Q415($0.16)($0.09)$10.29 million$12.30 millionViewListenView Earnings Details
5/4/2015Q315($0.01)$0.37$6.00 million$6.60 millionViewListenView Earnings Details
2/3/2015Q215($0.20)($0.06)$10.20 million$26.92 millionViewListenView Earnings Details
11/4/2014Q115($0.22)($0.21)$6.35 million$6.07 millionViewListenView Earnings Details
8/12/2014Q414($0.23)($0.22)$8.10 million$6.00 millionViewListenView Earnings Details
4/29/2014Q314($0.21)($0.20)$9.40 million$7.80 millionViewListenView Earnings Details
2/4/2014Q214($0.16)($0.13)$13.49 million$14.10 millionViewListenView Earnings Details
10/31/2013Q114($0.18)($0.13)$11.20 million$14.20 millionViewListenView Earnings Details
8/7/2013Q4 2013($0.13)($0.06)$16.13 million$25.40 millionViewListenView Earnings Details
5/6/2013Q3 2013($0.14)($0.19)$14.54 million$10.00 millionViewListenView Earnings Details
2/4/2013Q2 2013($0.14)($0.10)$16.52 million$18.40 millionViewListenView Earnings Details
10/29/2012Q113($0.15)($0.13)$16.70 million$15.80 millionViewN/AView Earnings Details
8/13/2012($0.11)($0.09)ViewN/AView Earnings Details
4/30/2012($0.16)($0.11)ViewN/AView Earnings Details
1/30/2012($0.12)($0.06)ViewN/AView Earnings Details
5/2/2011($0.25)($0.20)ViewN/AView Earnings Details
1/31/2011($0.28)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Array BioPharma (NASDAQ:ARRY)
2017 EPS Consensus Estimate: ($0.94)
2018 EPS Consensus Estimate: ($1.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.22)($0.21)($0.22)
Q2 20173($0.27)($0.20)($0.22)
Q3 20173($0.31)($0.22)($0.25)
Q4 20173($0.29)($0.21)($0.25)
Q1 20182($0.31)($0.19)($0.25)
Q2 20182($0.32)($0.18)($0.25)
Q3 20182($0.36)($0.18)($0.27)
Q4 20182($0.26)($0.21)($0.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Array BioPharma (NASDAQ:ARRY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Array BioPharma (NASDAQ:ARRY)
Insider Ownership Percentage: 3.18%
Institutional Ownership Percentage: 85.77%
Insider Trades by Quarter for Array BioPharma (NASDAQ:ARRY)
Institutional Ownership by Quarter for Array BioPharma (NASDAQ:ARRY)
Insider Trades by Quarter for Array BioPharma (NASDAQ:ARRY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/29/2017Kyle LefkoffDirectorSell38,865$12.31$478,428.15View SEC Filing  
3/28/2017Charles M BaumDirectorSell25,000$9.27$231,750.00View SEC Filing  
9/28/2016Redmile Group, LlcMajor ShareholderSell2,492,578$6.36$15,852,796.08View SEC Filing  
9/15/2016Redmile Group, LlcMajor ShareholderBuy400,000$3.51$1,404,000.00View SEC Filing  
1/20/2016Redmile Group, LlcMajor ShareholderBuy300,000$3.19$957,000.00View SEC Filing  
1/12/2016Redmile Group, LlcMajor ShareholderBuy75,000$3.60$270,000.00View SEC Filing  
1/11/2016Redmile Group, LlcMajor ShareholderBuy925,000$3.67$3,394,750.00View SEC Filing  
10/1/2015Redmile Group, LlcMajor ShareholderBuy782,592$4.58$3,584,271.36View SEC Filing  
8/25/2015Redmile Group, LlcMajor ShareholderBuy790,000$5.38$4,250,200.00View SEC Filing  
8/10/2015Redmile Group, LlcMajor ShareholderBuy1,048,993$5.80$6,084,159.40View SEC Filing  
3/3/2015Kyle LefkoffDirectorSell70,000$8.00$560,000.00View SEC Filing  
3/2/2015Andrews R RobbinsSVPSell21,576$8.25$178,002.00View SEC Filing  
3/2/2015Ron SquarerCEOSell40,000$8.25$330,000.00View SEC Filing  
9/16/2013Liam RatcliffeDirectorSell1,673,172$6.08$10,172,885.76View SEC Filing  
9/6/2013Liam RatcliffeDirectorSell577,286$5.79$3,342,485.94View SEC Filing  
8/2/2013John R MooreVPSell75,384$7.02$529,195.68View SEC Filing  
7/23/2013John R MooreVPSell5,000$6.50$32,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Array BioPharma (NASDAQ:ARRY)
Latest Headlines for Array BioPharma (NASDAQ:ARRY)
Source:
Loading headlines, please wait.

Social

Chart

Array BioPharma (ARRY) Chart for Tuesday, October, 24, 2017

This page was last updated on 10/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.